Passa al contenuto
Merck
Tutte le immagini(1)

Documenti fondamentali

Visualizza tutta la documentazione

C-907

Supelco

Clonazepam solution

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C15H10ClN3O3
Numero CAS:
1622-61-3
Peso molecolare:
315.71
Numero CE:
200-659-6
Numero MDL:
MFCD00057746
Codice UNSPSC:
41116107
ID PubChem:
329775195
NACRES:
NA.24

Grado

certified reference material

Stato

liquid

Caratteristiche

Snap-N-Spike®/Snap-N-Shoot®

Confezionamento

ampule of 1 mL

Produttore/marchio commerciale

Cerilliant®

drug control

Narcotic Licence Schedule B (Switzerland); psicótropo (Spain); Decreto Lei 15/93: Tabela IV (Portugal)

Concentrazione

1.0 mg/mL in methanol

tecniche

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

applicazioni

clinical testing

Formato

single component solution

Temperatura di conservazione

−20°C

Stringa SMILE

[O-][N+](=O)c1ccc2NC(=O)CN=C(c3ccccc3Cl)c2c1

InChI

1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
DGBIGWXXNGSACT-UHFFFAOYSA-N

Informazioni sul gene

human ... GABRA1(2554) , GABRA2(2555) , GABRA3(2556) , GABRA4(2557) , GABRA5(2558) , GABRA6(2559) , GABRB1(2560) , GABRB2(2561) , GABRB3(2562) , GABRD(2563) , GABRE(2564) , GABRG1(2565) , GABRG2(2566) , GABRG3(2567) , GABRP(2568) , GABRQ(55879)

Cerchi prodotti simili? Visita Guida al confronto tra prodotti

Categorie correlate

Descrizione generale

Clonazepam, marketed under trade names such as Klonopin and Rivotril, is a potent, long-acting benzodiazepine with anxiolytic, anticonvulsant, muscle relaxant and hypnotic properties. Clonazepam is prescribed for the treatment of epilepsy. This certified Snap-N-Spike® solution is suitable for use in GC/MS or LC/MS applications in forensic analysis, clinical toxicology, urine drug testing, or pain prescription monitoring.

Note legali

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Prodotti correlati

N° Catalogo
Descrizione
Determinazione del prezzo

A-915

7-Aminoclonazepam solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-916

7-Aminoclonazepam solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-917

7-Aminoclonazepam-d4 solution, 100 μg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

A-924

7-Aminoclonazepam-d4 solution, 1.0 mg/mL in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-033

Benzodiazepine Multi-component Mixture-8 solution, 250 μg/mL each component in acetonitrile, ampule of 1 mL, certified reference material, Cerilliant®

B-905

Benzodiazepine Internal Standard-3 solution, 0.5-1.0 mg/mL in acetonitrile, ampule of 1.0 mL, certified reference material, Cerilliant®

C-905

Clonazepam-d4 solution, 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

C-906

Clonazepam-d4 solution, 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

F-047

Flubromazolam solution, 1.0 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-159

Diclazepam solution, 1 mg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

M-197

Meclonazepam solution, 1 mg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

M-198

Meclonazepam-D3 solution, 100 μg/mL in methanol, certified reference material, ampule of 1 mL, Cerilliant®

D-160

Diclazepam-D4 solution, 100 μg/mL in acetonitrile, certified reference material, ampule of 1 mL, Cerilliant®

Avvertenze

Danger

Indicazioni di pericolo

H225,H301 + H311 + H331,H370

Classi di pericolo

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Organi bersaglio

Eyes,Central nervous system

Codice della classe di stoccaggio

3 - Flammable liquids

Classe di pericolosità dell'acqua (WGK)

WGK 2

Punto d’infiammabilità (°F)

49.5 °F - closed cup

Punto d’infiammabilità (°C)

9.7 °C - closed cup

Scegli una delle versioni più recenti:

Certificati d'analisi (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Documenti section.

Se ti serve aiuto, non esitare a contattarci Servizio Clienti

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

I clienti hanno visto anche

Slide 1 of 5

1 of 5

Clonazepam-d4 solution 100 μg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

C-905

Clonazepam-d4 solution

Triazolam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

T-910

Triazolam solution

Oxazepam solution 1 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

O-902

Oxazepam solution

Zolpidem solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

Z-017

Zolpidem solution

Bromazepam solution 1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Supelco

B-903

Bromazepam solution

G Chouinard
The Journal of clinical psychiatry, 48 Suppl, 29-37 (1987-10-01)
This is a report on the efficacy of clonazepam in the treatment of acute mania. The advantages of clonazepam over standard neuroleptics are its rapidity of action, its lack of toxicity, and, particularly important, the fact that it does not
Shigeru Morishita
Human psychopharmacology, 24(3), 191-198 (2009-03-31)
Clonazepam, first used for seizure disorders, is now increasingly used to treat affective disorders. We summarize the use of clonazepam to improve the management of depression. Clonazepam is useful for treatment-resistant and/or protracted depression, as well as for acceleration of
Raffaele Ferri et al.
Sleep medicine, 14(1), 24-29 (2012-10-27)
To analyze the differences in sleep structure and nocturnal motor activity between drug-free REM sleep behavior disorder (RBD) patients and those under therapy with clonazepam, and to evaluate the long-term longitudinal changes under continued therapy with clonazepam. Fifty-seven consecutive iRBD
Stuart J McCarter et al.
Sleep medicine, 14(3), 237-242 (2013-01-29)
REM sleep behavior disorder (RBD) is usually characterized by potentially injurious dream enactment behaviors (DEB). RBD treatment aims to reduce DEBs and prevent injury, but outcomes require further elucidation. We surveyed RBD patients to describe longitudinal treatment outcomes with melatonin
Taeko Sasai et al.
Parkinsonism & related disorders, 19(2), 153-157 (2012-09-20)
The clinical effectiveness of pramipexole (PPX), a candidate treatment for idiopathic rapid eye movement sleep behavior disorder (iRBD), varies among individuals. This study investigates factors associated with PPX effectiveness for treating RBD symptoms. Ninety-eight consecutive patients with RBD who had
Visualizza tutti i documenti correlati

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.